Phone: 08 8128 4364
Bachelor of Biotechnology (Hons) (Flinders University)
My research investigates the mechanism of action of Hsp90 proteins and their interaction with androgen receptor in prostate cancer. I study how the Hsp90 inhibitor drug AUY-922 affects the growth and death of prostate cancer cells and the levels and activity of androgen receptor, the main protein that drives prostate cancer. This work will help us know more about how prostate cancers respond to these drugs.
Publications (since 2010)
- Selth LA, Townley SL, Gillis JL, Tilley WD and Butler LM. Identification of prostate cancer-associated microRNA in circulation using a mouse model of disease. Method Mol Biol 1024: 235-246, 2013.
- Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD and Butler LM. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 4: 691-704, 2013.
- Centenera MM, Gillis JL, Hanson A, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T for the Australian Prostate Cancer BioResource, Tilley WD and Butler LM. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 18: 3562-3570, 2012- featured in Highlights section of Nat Rev Urol 9, 356 (July 2012).
- Selth LA, Townley S, Gillis JL, Ochnik A, MacFarlane R, Chi K, Murti K, Marshall VR, Tilley WD and Butler LM. Discovery of circulating microRNAs associated with prostate cancer using a mouse model of disease. Int J Cancer 131:652-61, 2012.
- Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD and Mackenzie PI. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide. Mol Pharmacol 78:714-22, 2010.